William Hait net worth and biography

William Hait Biography and Net Worth

Insider of Johnson & Johnson
William N. (Bill) Hait is Executive Vice President, Chief External Innovation, Medical Safety and Global Public Health Officer, and a member of the Johnson & Johnson Executive Committee. In this role Bill is responsible for leading external sourcing and creation of transformational innovation to help Johnson & Johnson achieve its mission to improve human health. He also oversees the Research and Development Management Committee that focuses on talent development and best-practice sharing within the Company’s R&D community, as well as Company efforts to advance mental health, improve healthcare for the world’s most vulnerable and underserved populations, and meet its obligations around product safety and ethical research, aligned with Our Credo.

Prior to this role, Bill served as Global Head, Johnson & Johnson External Innovation, where he built an enterprise-wide external R&D pipeline, creating innovative solutions utilizing the Company’s excellence in pharmaceuticals, medical devices, and consumer products. His team identified disruptive technologies and cutting-edge early innovations in disease areas of emphasis at Johnson & Johnson to eliminate disease through prevention, interception, and cures.

Bill joined Johnson & Johnson in 2007 and served as Global Therapeutic Area Head for Oncology from 2009 to 2011, and then as Global Head, Janssen Research & Development, from 2011 through 2018. Under his leadership, the company launched more than 20 new products and numerous line extensions, transforming the lives of millions of people around the world.

Before joining Johnson & Johnson, he was the founding Director of the (Rutgers) Cancer Institute of New Jersey. From 1993 to 2007 he was Professor of Medicine and Pharmacology and Associate Dean for Oncology Programs at the University of Medicine and Dentistry of New Jersey -- Robert Wood Johnson Medical School.

Bill graduated from the University of Pennsylvania. He then received an M.D. and Ph.D. cum Laude from the Medical College of Pennsylvania (former Women’s Medical College), received house staff and fellowship training at the Yale New Haven Hospital and joined the Yale University School of Medicine faculty in 1984. He became Associate Professor of Medicine and Pharmacology, Chief of the Division of Medical Oncology, Associate Director of the Yale University Comprehensive Cancer Center, Director of the Breast Cancer Unit and Co-Director of the Lung Cancer Unit. He is Board Certified in Internal Medicine and Medical Oncology.

He devoted time to numerous advisory and editorial boards and served in a range of scientific functions and committees including the Board of the American Association for Cancer Research and the Board of Scientific Advisors of the National Cancer Institute. He is currently a member of the Rutgers Cancer Institute of New Jersey Director's Advisory Board, Board of External Advisors for the Dana Farber/Harvard Cancer Center, the Stand Up to Cancer Scientific Advisory Board, the Board of Directors of Research! America, Vanderbilt University Biomedical Science Advisory Board, and the National Academy of Medicine’s President’s Advisory Council on Healthy Longevity.

Bill published more than 150 peer-reviewed manuscripts and received numerous awards and honors, including the Burroughs Welcome Award in Clinical Pharmacology and election to the American Society of Clinical Investigation. In addition, he was elected President of the American Association for Cancer Research (2007–2008) and Treasurer (2009-present), and in 2013 he was elected as a Fellow of the AACR Academy.

What is William Hait's net worth?

The estimated net worth of William Hait is at least $14.22 million as of October 24th, 2022. Mr. Hait owns 80,236 shares of Johnson & Johnson stock worth more than $14,221,029 as of November 26th. This net worth estimate does not reflect any other investments that Mr. Hait may own. Learn More about William Hait's net worth.

How do I contact William Hait?

The corporate mailing address for Mr. Hait and other Johnson & Johnson executives is ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ, 08933. Johnson & Johnson can also be reached via phone at (732) 524-0400. Learn More on William Hait's contact information.

Has William Hait been buying or selling shares of Johnson & Johnson?

During the past quarter, William Hait has sold $2,573,250.00 of Johnson & Johnson stock. Most recently, William Hait sold 15,000 shares of the business's stock in a transaction on Monday, October 24th. The shares were sold at an average price of $171.55, for a transaction totalling $2,573,250.00. Following the completion of the sale, the insider now directly owns 80,236 shares of the company's stock, valued at $13,764,485.80. Learn More on William Hait's trading history.

Who are Johnson & Johnson's active insiders?

Johnson & Johnson's insider roster includes Dominic Caruso (VP), Robert Decker (CAO), Joaquin Duato (CEO & Director ), Peter Fasolo (VP), Alex Gorsky (CEO), William Hait (Insider), Ronald Kapusta (CAO), Ashley McEvoy (EVP), Thibaut Mongon (VP), William Perez (Director), Michael Sneed (COO), Paulus Stoffels (VP), Kathryn Wengel (EVP), and Joseph Wolk (Exec. VP & CFO ). Learn More on Johnson & Johnson's active insiders.

Are insiders buying or selling shares of Johnson & Johnson?

During the last year, insiders at the sold shares 12 times. They sold a total of 319,488 shares worth more than $55,676,151.09. The most recent insider tranaction occured on November, 22nd when EVP Jennifer L Taubert sold 76,923 shares worth more than $13,598,447.94. Insiders at Johnson & Johnson own 0.4 % of the company. Learn More about insider trades at Johnson & Johnson.

Information on this page was last updated on 11/22/2022.

William Hait Insider Trading History at Johnson & Johnson

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/24/2022Sell15,000$171.55$2,573,250.0080,236View SEC Filing Icon  
4/21/2022Sell29,699$183.58$5,452,142.4280,236View SEC Filing Icon  
See Full Table

William Hait Buying and Selling Activity at Johnson & Johnson

This chart shows William Hait's buying and selling at Johnson & Johnson by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Johnson & Johnson Company Overview

Johnson & Johnson logo
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Read More

Today's Range

Now: $177.24
Low: $176.86
High: $178.12

50 Day Range

MA: $168.84
Low: $160.20
High: $177.01

2 Week Range

Now: $177.24
Low: $155.72
High: $186.69

Volume

3,056,125 shs

Average Volume

6,149,952 shs

Market Capitalization

$463.39 billion

P/E Ratio

24.69

Dividend Yield

2.55%

Beta

0.57